CAPTRUST Financial Advisors
CHRS icon

CAPTRUST Financial Advisors’s Coherus Oncology CHRS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Buy
18,814
+1,820
+11% +$2.97K ﹤0.01% 3185
2026
Q1 		$28.7K Buy
16,994
+3,880
+30% +$6.89K ﹤0.01% 2941
2025
Q4 		$18.6K Buy
13,114
+2,352
+22% +$3.43K ﹤0.01% 2717
2025
Q3 		$17.6K Sell
10,762
-1,310
-11% -$1.46K ﹤0.01% 2610
2025
Q2 		$8.83K Buy
12,072
+904
+8% +$781 ﹤0.01% 2500
2025
Q1 		$9.01K Sell
11,168
-317
-3% -$365 ﹤0.01% 2341
2024
Q4 		$15.8K Sell
11,485
-7,304
-39% -$8.19K ﹤0.01% 2275
2024
Q3 		$19.5K Buy
18,789
+7,393
+65% +$10.1K ﹤0.01% 2261
2024
Q2 		$19.7K Buy
11,396
+889
+8% +$1.79K ﹤0.01% 2174
2024
Q1 		$25.1K Buy
+10,507
New +$25.9K ﹤0.01% 2111
2023
Q4 		– Sell
-42,607
Closed -$159K – 2692
2023
Q3 		$159K Buy
42,607
+18,862
+79% +$87.1K ﹤0.01% 2353
2023
Q2 		$101K Buy
+23,745
New +$140K ﹤0.01% 2375
2022
Q3 		– Sell
-2,725
Closed -$20K – 2406
2022
Q2 		$20K Buy
2,725
+321
+13% +$2.79K ﹤0.01% 3369
2022
Q1 		$31K Buy
2,404
+2,250
+1,461% +$28.6K ﹤0.01% 3116
2021
Q4 		$2K Buy
154
+29
+23% +$507 ﹤0.01% 4392
2021
Q3 		$2K Sell
125
-513
-80% -$7.52K ﹤0.01% 4240
2021
Q2 		$9K Buy
638
+415
+186% +$5.88K ﹤0.01% 3587
2021
Q1 		$3K Buy
223
+98
+78% +$1.66K ﹤0.01% 3895
2020
Q4 		$2K Buy
+125
New +$2.23K ﹤0.01% 3091
2020
Q3 		– Sell
-2,000
Closed -$36K – 3069
2020
Q2 		$36K Buy
+2,000
New +$33.9K ﹤0.01% 1736

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

CAPTRUST Financial Advisors's CHRS Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Coherus Oncology (CHRS) stake by 11% in Q2 2026, buying an estimated $2.97K and bringing the position to 18,814 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

CAPTRUST Financial Advisors first reported a position in CHRS in Q2 2020 and has held it in 20 quarters since. The position peaked at $159K in Q3 2023. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • CAPTRUST Financial Advisors held 18,814 shares of Coherus Oncology worth $26.3K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 1,820 Coherus Oncology shares in Q2 2026, an estimated $2.97K.
  • Coherus Oncology made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3185 holding.
  • CAPTRUST Financial Advisors first reported a position in Coherus Oncology in Q2 2020 and has held it in 20 quarters since.
  • CAPTRUST Financial Advisors's Coherus Oncology position peaked at $159K in Q3 2023.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.